Update on the management of overactive bladder: patient considerations and adherence

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology. 2003;61(1):37–49.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur Urol. 2003;43(1):1–5.
   PubMed Web of Science ®Google Scholar
• Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006;147 Suppl 2:S80–S87.
   Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314.
   PubMed Web of Science ®Google Scholar
• Stewart WF, van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 2007;23(1):65–76.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395.
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am JManag Care. 2009;15 Suppl 4:S98–S107.
   Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6 Suppl 11:S574–S579.
   Google Scholar
• Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005;25(4):511–519.
   Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63(3):461–465.
   PubMed Web of Science ®Google Scholar
• Hobbs F, Stoops N. Demographic Trends in the 20th Century. Washington (DC): United States Census Bureau, United States Government Printing Office; 2002. Available from: http://www.census. gov/prod/2002pubs/censr-4.pdf. Accessed 2010 Oct 15.
   Google Scholar
• Benner JS, Becker R, Fanning K, Jumadilova Z, Bavendam T, Brubaker L. Bother related to bladder control and health care seeking behavior in adults in the United States. J Urol. 2009;181(6):2591–2598.
   Web of Science ®Google Scholar
• Morrison J, Birder L, Craggs M, et al. Neural control. In: Abrams P Cardozo L, Khoury S, Wein A, editors. Incontinence. Jersey: Health Publications, Ltd.; 2005:363–422.
   Google Scholar
• de Groat WC, Theobald RJ. Reflex activation of sympathetic pathways to vesical smooth muscle and parasympathetic ganglia by electrical stimulation of vesical afferents. J Physiol. 1976;259(1):223–237.
   Web of Science ®Google Scholar
• de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol. 2006;147 Suppl 2:S25–S40.
   Google Scholar
• Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350(8):786–799.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Storage and voiding symptoms: pathophysiological aspects. Urology. 2003;62 Suppl 5B:3–10.
   Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53.
   PubMed Web of Science ®Google Scholar
• Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50 Suppl 6A:57–67.
   Google Scholar
• Levin RM, Longhurst PA, Monson FC, Kato K, Wein AJ. Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl. 1990;3:9–26.
   PubMedGoogle Scholar
• Gosling JA, Kung LS, Dixon JS, Horan P, Whitbeck C, Levin RM. Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J Urol. 2000;163(4):1349–1356.
   PubMed Web of Science ®Google Scholar
• Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144(8):1089–1099.
   PubMed Web of Science ®Google Scholar
• Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80(24–25):2303–2307.
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279–290.
   PubMed Web of Science ®Google Scholar
• Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol. 2002;22(3):133–145.
   PubMedGoogle Scholar
• Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503–507.
   PubMed Web of Science ®Google Scholar
• Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129(3):416–419.
   PubMed Web of Science ®Google Scholar
• Ditropan package insert (Marion Merrell Dow – US), 1992. PDR.
   Google Scholar
• Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1998;35(5):515–520.
   Google Scholar
• Ditropan XL package insert (Ortho-McNeil Pharmaceutical, Inc.), 1999.
   Google Scholar
• Macdiarmid SA. The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Rev Urol. 2009;11(1):1–6.
   Google Scholar
• Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology. 2006;67(4):657–664.
   Web of Science ®Google Scholar
• Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001;18(7):1029–1034.
   PubMed Web of Science ®Google Scholar
• Mukhtar H, Khan WA. Cutaneous cytochrome P-450. Drug Metab Rev. 1989;20(2–4):657–673.
   PubMed Web of Science ®Google Scholar
• Oxytrol [package insert]. Corona, California, Watson Pharma, Incorporated, 2003.
   Google Scholar
• Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin in treatment of patients with urge urinary incontinence. J Urol. 2001;166(1):140–145.
   PubMed Web of Science ®Google Scholar
• Gelnique® prescribing information.
   Google Scholar
• Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother. 2009;10(18):3103–3111.
   PubMed Web of Science ®Google Scholar
• Rovner ES, Wein AJ. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol. 2002;41(1):6–14.
   PubMed Web of Science ®Google Scholar
• Olsson B, Szamosi J. Multiple-dose pharmacokinetics of a new once-daily extended-release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet. 2001;40(3):227–235.
   Web of Science ®Google Scholar
• Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int. 2006;97(2):400–403.
   PubMed Web of Science ®Google Scholar
• Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009;63(12):1715–1723.
   Web of Science ®Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45(4):420–429.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl. 2002;1:23–28.
   Web of Science ®Google Scholar
• Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325–350.
   Web of Science ®Google Scholar
• Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R. Solif-enacin succinate for the treatment of symptoms of overactive bladder. Clin Ther. 2006;28(9):1247–1272.
   Web of Science ®Google Scholar
• Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin. 2005;21(1):71–80.
   PubMed Web of Science ®Google Scholar
• Ellsworth P. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869–876.
   PubMedGoogle Scholar
• Nilvebrant L, Hallen B, Larsson G. Tolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997;60(13–14):1129–1136.
   PubMed Web of Science ®Google Scholar
• Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9(10):1787–1796.
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;4:CD003781.
   Web of Science ®Google Scholar
• Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;4:CD003193.
   Web of Science ®Google Scholar
• Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2005;3:CD005429.
   Google Scholar
• Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562.
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009;181(4):1764–1772.
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565–578.
   PubMed Web of Science ®Google Scholar
• Scarpero HM, Dmochowski RR. Muscarinic receptors: what we know. Curr Urol Rep. 2003;4(6):421–428.
   Google Scholar
• Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002;366(2):97–103.
   PubMed Web of Science ®Google Scholar
• Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci. 2010 Jul 2. Epub ahead of print.
   Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW; Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62(2):237–242.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR, et al; Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168(2):580–586.
   PubMed Web of Science ®Google Scholar
• Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D’Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46(1):8–13.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173(2):493–498.
   PubMed Web of Science ®Google Scholar
• Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface. 2004;17(11):54–60.
   Google Scholar
• Rosenblum N. Will the evolution of overactive bladder delivery systems increase patient compliance? Rev Urol. 2009;11(2):45–51.
   Google Scholar
• Fong RL. Violence as a barrier to compliance for the hypertensive urban African American. J Natl Med Assoc. 1995;87(3):203–207.
   PubMed Web of Science ®Google Scholar
• Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc. 2003;43(6):668–678.
   Google Scholar
• Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care. 2005;11 Suppl 4:S140–S149.
   Google Scholar
• Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health. 2005;8(4):495–505.
   PubMed Web of Science ®Google Scholar
• Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care. 2005;11 Suppl 4:S121–S129.
   Google Scholar
• Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183(3):1077–1081.
   PubMed Web of Science ®Google Scholar
• D’Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate- release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291–301.
   PubMed Web of Science ®Google Scholar